MARKET

ACRV

ACRV

Acrivon Therapeutics, Inc.
NASDAQ
2.160
-0.100
-4.42%
After Hours: 2.150 -0.01 -0.46% 18:14 12/19 EST
OPEN
2.250
PREV CLOSE
2.260
HIGH
2.280
LOW
2.120
VOLUME
767.71K
TURNOVER
--
52 WEEK HIGH
8.00
52 WEEK LOW
1.050
MARKET CAP
68.16M
P/E (TTM)
-1.0147
1D
5D
1M
3M
1Y
5Y
1D
Acrivon to provide ACR-368, ACR-2316 clinical data in January
TipRanks · 2d ago
Acrivon Therapeutics Said It Will Be Providing ACR-368 and ACR-2316 Clinical Data And Other Updates In January 2026
Benzinga · 2d ago
Acrivon Therapeutics Announces Upcoming Clinical Data Updates for ACR-368 and ACR-2316 Trials
Reuters · 2d ago
ACRIVON THERAPEUTICS TO ANNOUNCE CLINICAL UPDATE ON ITS ONGOING PHASE 2B STUDIES AND PLANNED CONFIRMATORY PHASE 3 TRIAL FOR ACR-368, INITIAL CLINICAL DATA ON ACR-2316, AND OTHER AP3 PIPELINE UPDATES
Reuters · 2d ago
Weekly Report: what happened at ACRV last week (1208-1212)?
Weekly Report · 4d ago
Weekly Report: what happened at ACRV last week (1201-1205)?
Weekly Report · 12/08 10:18
Weekly Report: what happened at ACRV last week (1124-1128)?
Weekly Report · 12/01 10:14
Optimistic Buy Rating for Acrivon Therapeutics, Inc. Driven by Promising ACR-368 Trial Developments
TipRanks · 11/25 11:15
More
About ACRV
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. It uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.

Webull offers Acrivon Therapeutics Inc stock information, including NASDAQ: ACRV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACRV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACRV stock methods without spending real money on the virtual paper trading platform.